AndronETalksNews
AndronETalksNews
The Hill
BY MAUREEN BRESLIN – 10/27/21 09:09 PM EDT
An affordable antidepressant has been found in a clinical trial to reduce the risk of hospitalization in high-risk adults with recently diagnosed COVID-19, according to a study published in The Lancet Global Health.
The drug, known as fluvoxamine, is a selective serotonin reuptake inhibitor (SSRI) commonly used in the treatment of depression, anxiety, obsessive-compulsive disorder and other mood disorders. Its low price makes it a desirable treatment option for less wealthy nations, the researchers wrote.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |